On October 26, 2025, Shenzhen Beimei Pharmaceutical Co., Ltd. (Beimei Pharma)successfully held a national investigator meeting for the Phase III clinical trial of TWYNEO® (Tretinoin, Benzoyl Peroxide)in Hangzhou, marking the official launch of this pivotal Phase III study for Chinese acne patients.Sponsored by Beimei Pharma, the study is led by Prof. Wu Wenyu of ...

Beimei Pharma announced that TWYNEO® (Tretinoin, Benzoyl Peroxide) received clinical trial approval from the NMPA on September 25, 2025. The approval permits “a Phase III clinical study evaluating efficacy and safety in patients aged 9 years and older with common acne,conducted as a multicenter, randomized, double-blind, placebo-controlled trial.”This clinical trial is pla...

September 26, 2024, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as "Beimei Pharmaceutical") self-developed productProcaterol Hydrochloride Oral Solution (trade name: 贝舒清®) has been successfully approved by the Chinese CDE, and Beimei Pharmaceutical is the MAH of this product.✦•✦✦✦ProcaterolHydrochloric Oral Solution is a respiratory...

September 14, 2024, Shenzhen Beimei Pharmaceutical Co., LTD. (hereinafter referred to as "Beimei Pharmaceutical") self-developed product Procaterol Hydrochloride Inhalation Solution (trade name:倍舒捷®)has been successfully approved by the Chinese CDE, and Beimei Pharmaceutical is the MAH of this product.Procaterol Hydrochloride Inhalation Solution is mainly u...

Shenzhen Beimei Pharmaceutical Co., Ltd. ("Beimei Pharma") announced that on May 15th, 2024, an asset purchase agreement (the "Agreement") was signed with Sol-Gel Technologies, Ltd. ("Sol-Gel", Nasdaq stock Code: SLGL) to acquire all relevant assets of dermatology product TWYNEO® in the mainland of China, Hong Kong, Macau, Taiwan and I...

On August 31, 2023, Dr. B.Partha Saradhi Reddy, Chairman of Hetero Labs Limited,Mr. Bheemireddy Murali Krishnar Reddy, President of Emerging Markets,Mr. Variyath Muraleedharan, VP of International Markets,Mr. Suman Reddy Bandi, Head of API,and Tanya Wang, BD of Formulation， together visited Shenzhen Beimei Pharmaceutical Co., Ltd. Ms. Wu Guangmei, C...

Recently, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as "Beimei Pharma") has completed a newfinancinground with investors including Jiangsu Jinqiao Private Equity Fund Management Co., Ltd., Nanshan SEIInvestment and Jiangsu Aosaikang Pharmaceutical Co., Ltd. This fund raisedwill be used to continue to promote the commercialization of seve...

August 2, 2023, Shenzhen BeimeiPharmaceutical Co., Ltd. (hereinafter referred to as "BeimeiPharmaceuticals") in collaboration with Hetero Labs Limited is pleased to announce that ourimported drug formulation "Lacosamide Oral Solution (Trade Name: 乐美定®)" has successfully received approval from the NMPA, the National Medical Products Administration,for...

On July 27, 2023, Shenzhen Beimei Pharmaceutical Co., LTD. (hereinafter referred to as "Beimei Pharmaceutical") first self-developed product "atomoxetine hydrochloride oral solution (trade name: 贝择思®)” has been successfully approved by the Chinese CDE for the treatment of attention deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6 years...